Tag: Justin Madders

The below Parliamentary question was asked by Justin Madders on 2015-12-14.

To ask the Secretary of State for Health, how much (a) his Department, (b) Public Health England, (c) NHS England and (d) each of his Department’s non-departmental public bodies spent on (i) iPads, (ii) iPhones, (iii) other smartphones and (iv) other tablet devices in each of the last five years; and how many of each such device were purchased in each such year.

Jane Ellison

Information about the number and cost of iPads, iPhones, other smartphones and other tablet devices purchased by the Department and its arm’s length bodies in each of the last five years is contained in the attached tables.

The below Parliamentary question was asked by Justin Madders on 2016-01-25.

To ask the Secretary of State for Transport, what the capital spend on transport was per head of population in (a) Ellesmere Port and Neston constituency, (b) the North West and (c) England in the last 12 months for which figures are available.

Andrew Jones

Figures on transport capital spend per head of population can be derived for the North West and England from the HM Treasury Country and Regional Analysis (CRA).

Data on spend per head on transport is not available at the level of Ellesmere Port and Neston Constituency.

The below Parliamentary question was asked by Justin Madders on 2016-02-02.

To ask the Secretary of State for Health, what steps he plans to take to ensure that out-of-hours GP services have access to patients’ medical records.

Alistair Burt

Summary Care Records are being introduced to improve the safety and quality of patient care. The Summary Care Record is a single electronic record held centrally so will give healthcare staff faster, easier access to essential information and help to give patients safe treatment during an emergency or when their general practitioner (GP) surgery is closed.

55.06 million people have had a Summary Care Record created and the Summary Care Record is currently enabled in 102 out of 154 Out of Hours GP Services.

The below Parliamentary question was asked by Justin Madders on 2016-03-01.

To ask the Secretary of State for Health, pursuant to the Answer of 11 February 2016 to Question 26284, what steps NHS England has taken to deal with potential conflicts of interests in the support offered by Deloitte to the development of its clinical commissioning policies; and if he will make a statement.

Ben Gummer

Deloitte is contracted to provide consultancy and advice to NHS England in support of its policy development programme for commissioned specialised services.

Deloitte is acting in an advisory capacity only and all decisions and governance processes associated with the policy development and adoption process have been retained by NHS England.

Where there has been potential for commercial in confidence information, this data and any associated analysis has been handled by NHS England alone.

The below Parliamentary question was asked by Justin Madders on 2016-03-15.

To ask the Secretary of State for Health, how much funding was allocated to Heathwatch England in each of the last three years; and how much such funding will be allocated in 2016-17 in cash terms and real terms.

Ben Gummer

Healthwatch England was allocated £4.083 million in 2013/14, £4.157 million in 2014/15, and £4.5 million in 2015/16. The figures are a combination of funding for core running costs and additional non-recurrent funding.

A final allocation for 2016/17 is yet to be finalised.

The below Parliamentary question was asked by Justin Madders on 2016-04-13.

To ask the Secretary of State for Health, which medicines have been reclassified from (a) prescription only medicine to pharmacy medicine status, (b) pharmacy medicine to general sales list medicine status and (c) prescription only medicine to general sales list medicine status in each of the last 25 years; for each of those medicines so reclassified what condition that medicine was designed to treat; and if he will make a statement.

George Freeman

The Government is committed to the continued reclassification of medicines from prescription only to pharmacy classification and from pharmacy to general sales list classification when it is safe to do so and there is a clear benefit to public health. This is an important part of empowering patients to manage their own care. The Government’s medicines regulator, the Medicines and Healthcare products Regulatory Agency, is at the forefront of moves to reclassify medicines to non-prescription and is recognised as a leader in Europe in this regard.

Over the years reclassification has been facilitated by improving the regulatory environment for manufacturers to achieve successful reclassification of their products. Amendments to legislation were introduced in 2002 to reduce the legislative burden for reclassification; new guidance was published in 2012 to streamline the process; and in 2015 a United Kingdom platform was set up to maximise stakeholder engagement with the aim of encouraging further reclassification of medicines.

Patient safety remains the prime consideration in any decision to make a medicine available without prescription.

We are unable to calculate the total difference in cost to the public purse following these medicine reclassifications.

The attached tables contain the information for each of the last 25 years on medicines reclassified from prescription only medicine (POM) to Pharmacy (P) medicine and P medicine to general sales list (GSL) medicine. There are no examples of medicines which have been reclassified from POM to GSL. Where relevant, brand names have been included in brackets.

The lists represent the first reclassification either from POM to P or P to GSL of the product and further extensions such as wider indications, additional pack sizes or higher strengths have not been included.

Not all products listed are currently available, for various reasons, including both commercial and regulatory.

The below Parliamentary question was asked by Justin Madders on 2016-05-04.

To ask the Secretary of State for Health, what advice he received from senior nurses before the decision to replace NHS bursaries with student loans was announced in the Autumn Statement.

Ben Gummer

The Government received and considered a broad range of representations from a number of stakeholders during the Spending Review process including discussions with leading nursing professionals in the Department and its arm’s length bodies.

The below Parliamentary question was asked by Justin Madders on 2016-05-26.

To ask the Secretary of State for Health, what funding has been allocated by Health Education England for clinical placements for the new nurse training places his Department plans to deliver by the end of the Parliament.

Ben Gummer

Following the reforms to higher education healthcare funding, the Government, through Health Education England, will retain the responsibility for commissioning and funding the minimum numbers of clinical placements required to produce sufficient healthcare graduates. The Government is consulting on the widest possible funding solutions to ensure there is sufficient placement capacity across the system, in order to match the expanded number of training places created by the reforms.

The below Parliamentary question was asked by Justin Madders on 2016-06-07.

To ask the Secretary of State for Health, what proportion of Sustainability and Transformation Plans have been submitted to his Department; and what the deadline is for such plans to be submitted.

George Freeman

No Sustainability and Transformation Plans have been submitted yet. Draft submissions will be made to the national arm’s length bodies and are due on 30 June 2016. These documents will be discussed with footprints in July 2016.

Plans will have no status until they are agreed. Footprints are at different starting points, and so the degree of detail that will be provided by 30 June 2016 will vary. Therefore, rather than expecting to have one ‘sign-off’ moment for all 44 plans, it is anticipated that this will occur in a series of waves over the coming weeks and months, with those areas who are more advanced achieving earlier sign off than those who will require more work.

The below Parliamentary question was asked by Justin Madders on 2016-06-14.

To ask the Secretary of State for Health, how many secondary breast cancer nurses there are in England.

Ben Gummer

Information on the number of secondary breast cancer nurses in England is not collected by the Department.

It is for local National Health Service organisations with their knowledge of the healthcare needs of their local population to invest in training for specialist skills and to deploy specialist nurses.